Abstract | Background: Methods: A meta-analysis of randomized controlled trials (RCTs) was performed to investigate the real efficacy of sacubitril-valsartan on blood pressure, compared with angiotensin receptor blockers or placebo. A lifetime Markov model was developed to compare the cost utility of sacubitril-valsartan vs. valsartan. The primary outcome was the incremental cost-utility ratio (ICUR), representing the ratio of incremental costs to the incremental utility. The willingness-to-pay (WTP) threshold was three times of per capita gross domestic product ( GDP) in China in 2021. Sacubitril-valsartan was considered cost-effective if the ICUR obtained was lower than the WTP threshold, otherwise, sacubitril-valsartanis was not cost-effective. Results: A total of 10 RCTs of 5,781 patients were included in the meta-analysis. For comparison of sacubitril-valsartan 400 mg/day vs. valsartan 320 mg/day, a reduction in blood pressure (BP) of -5.97 (-6.38, -5.56) (p < 0.01) was observed. Cost-utility analysis showed that for a 60-year-old patient with hypertension, if sacubitril-valsartan was prescribed as the antihypertensive agent, he had a life expectancy of 11.91 quality-adjusted life-years (QALYs) with costs of 65,066 CNY, and if valsartan was prescribed as the antihypertensive agent, the life expectancy would be 11.82 QALY with costs of 54,769 CNY; thus, an ICUR of 108,622 CNY/QALY was obtained, lower than the WTP threshold. Conclusion: Compared with valsartan, sacubitril-valsartan is more effective in reducing blood pressure and may result in more quality-adjusted life-year, although with higher costs. Sacubitril-valsartan is cost-effective for hypertension in the current China setting under the willingness-to-pay threshold of 3 times of per capita GDP.
|
Authors | Yake Lou, Ying Yu, Jinxing Liu, Jing Huang |
Journal | Frontiers in public health
(Front Public Health)
Vol. 10
Pg. 959139
( 2022)
ISSN: 2296-2565 [Electronic] Switzerland |
PMID | 36062091
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | Copyright © 2022 Lou, Yu, Liu and Huang. |
Chemical References |
- Aminobutyrates
- Antihypertensive Agents
- Biphenyl Compounds
- sacubitril
- Valsartan
|
Topics |
- Aminobutyrates
- Antihypertensive Agents
(pharmacology, therapeutic use)
- Biphenyl Compounds
- Cost-Benefit Analysis
- Heart Failure
(drug therapy)
- Humans
- Hypertension
(drug therapy)
- Male
- Middle Aged
- Randomized Controlled Trials as Topic
- Valsartan
(pharmacology, therapeutic use)
|